^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    onvapegleukin alfa (TransCon IL-2 β/γ)

    i
    Associations
    News

    Trials

    Company:
    Ascendis
    Drug class:
    CD122 agonist, IL-2R agonist, IL-2Rγ agonist
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (IL Believe) (NCT05081609)
    Phase 1/2
    Ascendis Pharma Oncology Division A/S
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    01/11/2022
    Primary completion :
    08/01/2027
    Completion :
    08/01/2029
    IL2
    |
    Keytruda (pembrolizumab) • Kadcyla (ado-trastuzumab emtansine) • onvapegleukin alfa (TransCon IL-2 β/γ) • resiquimod SR (TransCon TLR7/8 Agonist)